Cargando…
Influence of CYP2C19*2/*17 genotype on adverse drug reactions of voriconazole in patients after allo-HSCT: a four-case report
PURPOSE: Voriconazole (VCZ) is a new-generation triazol antifungal agent. CYP2C19 mutations have been reported to cause variability in VCZ pharmacokinetics, and thus lead to undesirable effects of pharmacotherapy. We observed four Caucasian patients who underwent allogenic hematopoietic stem cell tr...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5427156/ https://www.ncbi.nlm.nih.gov/pubmed/28247033 http://dx.doi.org/10.1007/s00432-017-2357-y |
_version_ | 1783235614616846336 |
---|---|
author | Beata, Sienkiewicz Donata, Urbaniak-Kujda Jarosław, Dybko Tomasz, Wróbel Anna, Wiela-Hojeńska |
author_facet | Beata, Sienkiewicz Donata, Urbaniak-Kujda Jarosław, Dybko Tomasz, Wróbel Anna, Wiela-Hojeńska |
author_sort | Beata, Sienkiewicz |
collection | PubMed |
description | PURPOSE: Voriconazole (VCZ) is a new-generation triazol antifungal agent. CYP2C19 mutations have been reported to cause variability in VCZ pharmacokinetics, and thus lead to undesirable effects of pharmacotherapy. We observed four Caucasian patients who underwent allogenic hematopoietic stem cell transplantation, treated with voriconazole for prevention of fungal infections, to establish the impact of CYP2C19*2/*17 genotype on side effect occurrence. METHODS: Genetic testing for CYP2C19 allele*2 and*17 was performed using two PCR-RFLP methods established by Goldstein and Blaisdell, and Sim et al. All four patients presented CYP2C19*2/*17 genotype. RESULTS: The patients suffered from gastrointestinal, dermatological, neurological, hepatobiliary and renal adverse drug reactions (ADR). ADR could be best described by the use of VCZ. Other drugs potentially causing side effects were also taken into consideration. The presented complications were temporary and did not force dosage regimen adjustments or discontinuation of pharmacotherapy. After 2 months, the patients were discharged from hospital. CONCLUSIONS: Drug–drug interactions and ADR may occur even if an agent is used for prophylaxis only. We, therefore, should use any available tools for pharmacotherapy optimization—also genetic testing. |
format | Online Article Text |
id | pubmed-5427156 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-54271562017-05-26 Influence of CYP2C19*2/*17 genotype on adverse drug reactions of voriconazole in patients after allo-HSCT: a four-case report Beata, Sienkiewicz Donata, Urbaniak-Kujda Jarosław, Dybko Tomasz, Wróbel Anna, Wiela-Hojeńska J Cancer Res Clin Oncol Original Article – Clinical Oncology PURPOSE: Voriconazole (VCZ) is a new-generation triazol antifungal agent. CYP2C19 mutations have been reported to cause variability in VCZ pharmacokinetics, and thus lead to undesirable effects of pharmacotherapy. We observed four Caucasian patients who underwent allogenic hematopoietic stem cell transplantation, treated with voriconazole for prevention of fungal infections, to establish the impact of CYP2C19*2/*17 genotype on side effect occurrence. METHODS: Genetic testing for CYP2C19 allele*2 and*17 was performed using two PCR-RFLP methods established by Goldstein and Blaisdell, and Sim et al. All four patients presented CYP2C19*2/*17 genotype. RESULTS: The patients suffered from gastrointestinal, dermatological, neurological, hepatobiliary and renal adverse drug reactions (ADR). ADR could be best described by the use of VCZ. Other drugs potentially causing side effects were also taken into consideration. The presented complications were temporary and did not force dosage regimen adjustments or discontinuation of pharmacotherapy. After 2 months, the patients were discharged from hospital. CONCLUSIONS: Drug–drug interactions and ADR may occur even if an agent is used for prophylaxis only. We, therefore, should use any available tools for pharmacotherapy optimization—also genetic testing. Springer Berlin Heidelberg 2017-02-28 2017 /pmc/articles/PMC5427156/ /pubmed/28247033 http://dx.doi.org/10.1007/s00432-017-2357-y Text en © The Author(s) 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Original Article – Clinical Oncology Beata, Sienkiewicz Donata, Urbaniak-Kujda Jarosław, Dybko Tomasz, Wróbel Anna, Wiela-Hojeńska Influence of CYP2C19*2/*17 genotype on adverse drug reactions of voriconazole in patients after allo-HSCT: a four-case report |
title | Influence of CYP2C19*2/*17 genotype on adverse drug reactions of voriconazole in patients after allo-HSCT: a four-case report |
title_full | Influence of CYP2C19*2/*17 genotype on adverse drug reactions of voriconazole in patients after allo-HSCT: a four-case report |
title_fullStr | Influence of CYP2C19*2/*17 genotype on adverse drug reactions of voriconazole in patients after allo-HSCT: a four-case report |
title_full_unstemmed | Influence of CYP2C19*2/*17 genotype on adverse drug reactions of voriconazole in patients after allo-HSCT: a four-case report |
title_short | Influence of CYP2C19*2/*17 genotype on adverse drug reactions of voriconazole in patients after allo-HSCT: a four-case report |
title_sort | influence of cyp2c19*2/*17 genotype on adverse drug reactions of voriconazole in patients after allo-hsct: a four-case report |
topic | Original Article – Clinical Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5427156/ https://www.ncbi.nlm.nih.gov/pubmed/28247033 http://dx.doi.org/10.1007/s00432-017-2357-y |
work_keys_str_mv | AT beatasienkiewicz influenceofcyp2c19217genotypeonadversedrugreactionsofvoriconazoleinpatientsafterallohsctafourcasereport AT donataurbaniakkujda influenceofcyp2c19217genotypeonadversedrugreactionsofvoriconazoleinpatientsafterallohsctafourcasereport AT jarosławdybko influenceofcyp2c19217genotypeonadversedrugreactionsofvoriconazoleinpatientsafterallohsctafourcasereport AT tomaszwrobel influenceofcyp2c19217genotypeonadversedrugreactionsofvoriconazoleinpatientsafterallohsctafourcasereport AT annawielahojenska influenceofcyp2c19217genotypeonadversedrugreactionsofvoriconazoleinpatientsafterallohsctafourcasereport |